本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
年僅 20 歲的網球新秀 Carlos Alcaraz，自 10 歲起就一直使用 BABOLAT 的球拍參賽並獲勝，這項合作將至少持續到 2030 年。他與 1875 年在法國成立的網球專業公司 Babolat 的合約會延長七年，該消息之前已於紐約宣布。 紐約2023年8月25日 /美通社/ -- 更多信息：https://www.babolat.com/news-articles-blog-alcaraz-partnership-2030/alcaraz-partnership-2030.html?section=news World No. 1 Carlos Alcaraz and BABOLAT, the world leading tennis brand, announce partnership extension for 7 years until 2030 這位新晉的溫布頓網球錦標賽冠軍自 2022 年在美國網球公開賽上勝出以來，一直使用 BABOLAT Pure Aero 98 球拍和 BABOLAT RPM Blast 球拍線。他與 BABOLAT 行政總裁 Eric BABOLAT 一同簽署續約。Babolat 接近 150 年來一直為全球的網球愛好者提供裝備，從俱樂部球員到多位有史以來最優秀的冠軍：例如 René Lacoste、Björn Borg、Pete Sampras、李娜、Kim Clijsters 或 Rafa Nadal。 Alcaraz 表示：「在過去的 10 年來，Babolat 的專家們一直與我保持緊密合作，提供最佳的網球裝備以提升我的表現。使用 Pure Aero 98 配上 RPM Blast 球拍線上場，對我來說不僅僅是擁有一個網球拍，這意味著我是 BABOLAT 大家庭的一員，我把 BABOLAT 的成員視為我團隊的一部分。他們仔細聆聽我的需求和回饋，這是一個持續而有建設性的雙向過程。因此，我一直對球拍和球拍線的性能和手感十分滿意，延長這項長期合作關係是理所當然。」 Carlos Alcaraz 在 10 歲時於西班牙與 BABOLAT 簽署了他的第一份合約。他在 13 歲時加入國際 BABOLAT 團隊，現時年僅 20 歲的他成為網球歷史上獲得世界排名 No 1 的最年輕選手，並且已經贏得了兩個大滿貫冠軍（2022 年美國網球公開賽，2023 年溫布頓網球錦標賽）。 Alcaraz 從 4 歲開始打網球，一直都使用 BABOLAT 的球拍和球拍線。從 2022 年美國網球公開賽，Carlos 一直使用 Pure Aero 98 球拍，這是 Pure Aero VS 的升級版本，並配搭 BABOLAT 的 RPM Blast 球拍線（規格 130/16）。 如需更多資訊、圖片和影片內容，請前往：https://www.babolat.com/news-articles-blog-alcaraz-partnership-2030/alcaraz-partnership-2030.html?section=news 聯絡方式：shirley@zrcommunication.com
The Legendary Hospitality Brand Debuts in Macau with Approximately 450 Luxurious Suites, Creative Culinary and Design Collaborations, a Stunning Art Collection and More MACAU, Aug. 25, 2023 /PRNewswire/ -- Galaxy Macau™, in partnership with Accor and Raffles Hotels & Resorts, today proudly launched the soft opening of the integrated resort's spectacular new property Raffles at Galaxy Macau. The highly anticipated all-suite property is the first entry into Macau for the legendary Raffles brand, which is also the seventh hospitality brand to be established within the ever-expanding estate of Galaxy Macau. With approximately 450 luxurious suites, Raffles at Galaxy Macau is raising the bar for luxury hospitality in the region. A grand opening celebrating the addition of the remaining signature restaurants, bar, and a spa is expected towards the end of the year. A New Landmark in Macau and CotaiSince 1887, Raffles has been synonymous with the pinnacle of luxury hospitality, and is famed around the world for its personalized service, time-honored traditions, and exceptional attention to detail. Marking the latest chapter in the brand's storied 136-year history, Raffles at Galaxy Macau takes the guest experience to unprecedented heights and sets new standards for sophisticated opulence. Located on the resort's east promenade, the new property is a stunning architectural landmark, with two enormous LED screens offering possibilities for displays that can be seen right across Macau and neighboring Hengqin island. The building also features a glass airbridge that connects the two towers on every floor and offers breathtaking vistas towards the Macau skyline and over the resort. Spectacular East-Meets-West Interiors and ServicesReflecting Macau's rich East-Meets-West heritage and modern-day vibrancy, Raffles at Galaxy Macau immerses guests in impressive curated spaces that blend the storied traditions of the Raffles brand with the dynamic energy of Galaxy Macau. Paying tribute to Galaxy Macau's brand heritage, and symbolic of beauty, good luck, and royalty, the property features subtle peacock motifs throughout in the form of a geometric pattern that flows from the beautifully etched glass motifs on the lobby ceilings to the suspended ceilings in the residential suites. Imagined as the residence of a fictional 14th-century Italian merchant with an extensive collection of unique artifacts from around the world, the luxurious property is decorated throughout with exquisite art pieces, showcasing detailed craftsmanship and precious materials, from Italian white Statuario marble to hand-crafted crystal chandeliers. Guests will enjoy a personalized and memorable experience through Raffles' legendary hallmark butlers and doormen in their iconic uniforms. An Art-filled SanctuaryAt the heart of Raffles at Galaxy Macau is the showstopping lobby, an art-filled garden sanctuary where the interior and exterior come together to form one stunning space illuminated by natural light. Landscaped with 90 trees, 50,000 shrubs, and seasonal flowers, this space celebrates the beauty of nature with a sustainable design that conserves energy, saves water, and reduces carbon. Here, guests also encounter a magnificent collection of art pieces themed around the four seasons that also pay tribute to the beauty of Asian nature and the spirit and character of the Raffles brand. Curated in Singapore, the collection features artworks by an eclectic selection of artists from around the world, including: 'In Bloom', a pair of monumental works by Dutch sculptor Joris Kuipers located on Ground Level; also on the Ground Level, 'Festive Times', a metal sculpture with snowflake patterns designed by Singaporean artist Sun Yu-Li; 'Evergreen' by China's Chen Chun Hua, a huge installation composed of 222 porcelain magnolia flowers; and 'Relationship', a trio of mesmerizing glass sculptures by Bulgarian-born artist Latchezar Boyadjiev. Each artwork is multidimensional and can be experienced differently depending on the viewing angle or the time of day or night. A Sparkling CenterpieceTaking center stage at the property's stunning lobby is the Raffles Lounge & Terrace, which offers traditional European afternoon tea with a twist, including an Éclair Trolley wheeled around with a selection of exotic delicacies, as well as an array of all-day dining options curated by the French culinary artist Yorick Soh Chin Chiang, the newly appointed Chef de Cuisine of Raffles Lounge & Terrace. By night, guests can enjoy a pianist's live performance on one of the world's finest handcrafted pianos alongside the Champagne and Oyster Bar. Raffles Lounge & Terrace will also serve the Raffles signature Singapore Sling alongside a very Macau-apt Million Dollar Cocktail—to be created by a collaboration with noted 50 Best Bars legend, Antonio Lai. Cascading above the Lounge is a custom-made 15-metre high chandelier formed of 500,000 crystals and 23,000 crystal rods that connect seamlessly to resemble a diamond. This iconic piece floats against a programmable backlit glass ceiling and weighs a colossal 4,800kg. Raffles Lounge & Terrace is also home to "Green Art Wall", a 70-meter expanse that incorporates hundreds of plants and LED lights to create a unique natural and artistic spectacle for guests on arrival, and a glass ceiling, which uses more than 30,000 individually programmable LED nodes to create an imaginary sky that can express various different moods and scenes. "Kaleidoscope" by Singaporean artist Sun Yu-Li, meanwhile, is a striking three-meter-tall sculpture that uses changing lights to hint at nature while giving off a distinctly Macau vibe. Coming SoonLooking ahead to the grand opening later in the year, guests will have the opportunity to experience an array of world-class collaborations that reflect the region's finest culinary and design talents. Chef and Sushi Master Masaaki Miyakawa, one of only five Michelin-three-starred sushi chefs in Japan, will helm a new signature Sushi-Kappo concept. There will also be an unexpected and modern take on Raffles' iconic Long Bar. Crafted by celebrated interior designer Joyce Wang, the Long Bar will feature a curated cocktail list, including an official Macau Sling, created by Asia's 50 Best Bars legend Antonio Lai. About RafflesSince its inception in Singapore in 1887, Raffles Hotels & Resorts has set the standard for luxury hospitality throughout the world, and is renowned for introducing private butlers, the creation of the Singapore Sling in 1915 by iconic bartender Ngiam Tong Boon, and its enduring legendary service. Raffles at Galaxy Macau joins 18 distinctive and ultra-luxurious Raffles hotels situated in prestigious locations around the globe, including Shenzhen and Hainan in China as well as Singapore, London (2023), Paris, Istanbul, Boston (2023), Doha, Dubai, Warsaw, Jakarta, Seychelles, Maldives, Udaipur, and other world-renowned destinations. Queen Elizabeth II, Charlie Chaplin, Elizabeth Taylor, and many more illustrious celebrities have stayed with Raffles over the years, adding even more color to the legend of the brand. About Galaxy MacauAs one of the world's leading integrated resorts, hospitality and entertainment companies, Galaxy Macau offers the largest collection of luxury hospitality brands in Macau. These include StarWorld Hotel, Banyan Tree Macau, Galaxy Hotel, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel and the soon-to-open Raffles at Galaxy Macau and Andaz Macau. The launch of Raffles at Galaxy Macau further solidifies Galaxy Macau's reputation as Asia's premier integrated resort and brings another differentiated luxury perspective to Galaxy Macau's growing portfolio and estate. Guests of Raffles at Galaxy Macau will have easy access to more than 1.1 million square meters of entertainment, shopping, dining and leisure attractions under one roof. The exterior of Raffles at Galaxy Macau features a pair of enormous LED screens and a glass airbridge that connects the two towers on every floor. Guests experience Raffles’ legendary service through the doormen in their iconic uniforms from the moment they arrive. “Relationship” by Latchezar Boyadjiev is among the elegant artworks on display at Raffles Lobby. Raffles Lounge & Terrace offers a tailored take on the classic European afternoon tea experience. Guests can savor an iconic Singapore Sling at Raffles Lounge & Terrace. For high resolution images, please visit the photo library:https://www.galaxymacaulibrary.com/gallery/Raffles-at-Galaxy-Macau-Soft-Opening/G0000l88Z83015EoPassword: galaxy About Galaxy Macau Integrated Resort Galaxy Macau™, The World-class Luxury Integrated Resort delivers the "Most Spectacular Entertainment and Leisure Destination in the World". Developed at an investment of HK$43 billion, the property covers 1.1 million square metres of unique entertainment and leisure attractions that are unlike anything else in Macau. Six award-winning world-class luxury hotels provide close to 4,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world's longest Skytop Adventure Rapids at 575 metres, the largest Skytop Wave Pool with waves up to 1.5 metres high and 150-meter pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz-Carlton Spa, Macau help guests relax and rejuvenate. As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies; Galaxy Promenade is the hottest shopping destination featuring the latest in fashion and curated experiences in Macau. Spanning over 100,000 square meters, luxury flagship stores, lifestyle boutiques and our selection of labels are among the more than 200 world-renowned brands for a world-class shopping journey; Galaxy Cinemas, a 10-theatre 3D Cineplex boasting 4K laser projection; CHINA ROUGE, one-of-a-kind deluxe lounge that evokes the glitz and glamor of Shanghai's golden era with entertainment in luxury and style; and Foot Hub presents the traditional art of reflexology to make you feel more relaxed and revitalized. For Authentic Macau Flavours & Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 different Authentic Macau & Asian Flavours at its Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events. Meeting, incentive and banquet groups are also well looked after with a portfolio of unique venues in Galaxy Macau and a professional service staff. Galaxy Macau is set to begin a new chapter, with the opening of two world-class luxury hotels – Raffles at Galaxy Macau, to be soft opened on August 16, and Andaz Macau, to be opened on September 15. Galaxy International Convention Center (GICC) is the latest addition to the Group's ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world-class event venue featuring 40,000 sqm of total flexible MICE, and a 16,000-seat Galaxy Arena – the largest indoor arena in Macau. For more details, please visit www.galaxymacau.com, www.broadwaymacau.com.mo and www.galaxyicc.com. About RafflesRaffles Hotels & Resorts, founded in Singapore in 1887, is where heritage meets modern hotelcraft. Raffles hotels, resorts and residences are places where ideas are born, history is made and stories and legends are created. At landmark addresses around the world, Raffles' well-travelled guests and residents enjoy experiences that are culturally enriching, intellectually stimulating and always respectful of local communities, heritage and the environment. From one generation to the next, visitors arrive as guests, leave as friends and return as family. Raffles can be found in key international locations including Singapore, Paris, Istanbul, Dubai, Doha, Maldives, Udaipur, Phnom Penh, and Bali; with flagship openings upcoming in London, Boston and Macau. Progressively shaping the future of luxury hospitality as part of Accor, Raffles benefits from a world-class infrastructure and is a participating brand in the Group's lifestyle loyalty and guest recognition programme, ALL - Accor Live Limitless. raffles.com | all.accor.com | group.accor.com
SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months ended June 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023. Dr. Jay Mei, Antengene's Founder, Chairman and CEO, said, "In the first half of this year, Antengene has achieved significant progress across its clinical programs. We are very encouraged that the mTORC1/2 inhibitor ATG-008, a drug candidate in late-stage clinical development, continues to show impressive and robust therapeutic potential in patients with cervical cancer with expanded patient enrollment. Meanwhile, we have made big strides with our global rights assets, particularly ATG-022 (Claudin 18.2 antibody-drug conjugate) and ATG-101 (PD-L1/4-1BB bispecific antibody), two clinical stage global rights programs in dose escalation studies that have already reported partial responses (PRs) at clinical centers at low dose levels. Furthermore, ATG-031, one of our in-house developed programs, has been cleared by the US FDA to enter a clinical study, thus becoming the world's first CD24 monoclonal antibody entering clinical development in oncology. We look forward to releasing more clinical data as we progress into the next few months. While making rapid advances in clinical development, we entered into a landmark partnership with Hansoh Pharma, one of the largest pharmaceutical companies in China. We are confident that this partnership will further expand the commercial reach of XPOVIO® in China and boost the opportunities for the drug upon additional NRDL listings and indication expansions. During the same period, we delivered on multiple commercial milestones for XPOVIO® in our APAC markets, namely the recent regulatory approval for the drug in Hong Kong China, NDA submission in Indonesia, expanded insurance coverage by the Australian Pharmaceutical Benefits Scheme (PBS) for the two XPOVIO® regimens, and inclusion into the Cancer Drug List in Singapore." Dr. Mei continued, "With the rapid progress in our differentiated clinical portfolio, positive early results from multiple trials, momentous growth trajectory for XPOVIO®, and a solid cash position, we are well positioned to maintain steady progress in our global R&D pipeline and deliver on our mission of bringing more transformative medicines to cancer patients around the world." 1. Excellent progress in first/best-in-class global rights clinical programs with clinical readouts beginning this fall Antengene has built an expansive pipeline of oncology drugs at various stages going from clinical to commercial. This pipeline comprises 6 global rights assets and 3 assets with rights for the APAC region. ATG-022 (Claudin 18.2 antibody-drug conjugate), with activity across a range of Claudin 18.2 expression levels, advanced to Phase I in Australia and the Mainland of China, and granted two Orphan Drug Designations (ODD) consecutively by the U.S. Food and Drug Administration (FDA) for treatment of gastric and pancreatic cancers. The drug is currently enrolling patients in the dose escalation phase, and a PR has already been reported by the clinical center earlier than the projected efficacious dose range. ATG-031 (anti-CD24 monoclonal antibody), a potential first-in-class program to target the "don't eat me" pathways, has successfully achieved US IND clearance for its Phase I trial. Our preclinical data suggest that CD24 is a target not expressed on human red blood cells, meaning that it will unlikely cause anemia issues commonly seen in molecules targeting CD47. Moreover, CD24 has higher tumor expression compared to CD47, making it a differentiated, high-potential approach to this exciting macrophage-regulating pathway. Antengene has selected multiple centers across the US for this clinical trial, with the MD Anderson Cancer Center in Houston, TX as the leading clinical site which is currently in active preparation for initiation. As part of the site initiation process, the Scientific Review Committee of MD Anderson Cancer Center has granted approval, putting us on a solid track to initiate enrollment in the fourth quarter of this year. ATG-101 (PD-L1/4-1BB bispecific antibody) has been designed to target PD-1/PD-L1 resistant cancers, supported by conditional 4-1BB activation of an enhanced T-cell response. The program is currently in dose escalation cohorts in its study spanning the Mainland of China, Australia, and the United States. The study is approaching the biologically active dose with good tolerability, and has already reported PR and durable stable diseases (SDs) in patients treated at low doses levels. Notably, from low dose level, SD has been observed in the longest-treated patient who had been on the drug for over a year. ATG-037 (CD73 inhibitor), which shows preclinical activity in the CD73 pathway without a hook effect, is advancing through a dose escalation study. Patients are being enrolled at both Australian and Chinese sites. The trial was designed to include a dose escalation study of ATG-037 monotherapy and in combination with pembrolizumab, to assess the potential for additional clinical benefits. At present, a total of 13 patients have started the combination treatment. ATG-017 (ERK1/2 inhibitor), a small molecular kinase inhibitor, has reached RP2D for monotherapy and successfully progressed to a combination dose expansion study, in conjunction with nivolumab, in the US and Australia. ATG-018 (ATR inhibitor), a unique small molecule inhibitor, is making smooth progress through its dose escalation phase. 7 patients are with stable disease out of 12 efficacy evaluable patients at low dose levels. AACR posters highlighted preclinical proof-of-concept data for three clinical programs: ATG-031 (anti-CD24 monoclonal antibody), ATG-017 (ERK1/2 inhibitor), ATG-037 (CD73 inhibitor) and a new research program: an LILRB4 antagonist antibody, ATG-034. 2. Encouraging clinical results for mid-to-late-stage APAC programs ATG-008 (mTORC1/2 inhibitor) unique, differentiated results in cervical cancer - The Phase II "TORCH-2" study is currently enrolling both checkpoint inhibitor (CPI)-naïve and CPI-pre-treated cervical cancer patients. Based on the latest data review as of August 23rd, 2023, out of the 31 CPI-naïve patients who received treatment (and 28 who had at least one tumor assessment), the objective response rate (ORR) was observed to be 46.4%. Among the 17 patients with prior CPI treatment (and 15 patients who had at least one tumor assessment), the ORR was observed to be 26.7%. Updated clinical data will be presented in the Antengene Annual R&D Day in November. Selinexor (XPO1 inhibitor) expansion opportunities in Myelofibrosis and endometrial cancer - These clinical data demonstrate the deep and broad expansion potential of selinexor beyond the initial indications of multiple myeloma and diffuse large B-cell lymphoma. Myelofibrosis: Results from the "XPORT-MF-034" study evaluating selinexor in combination with ruxolitinib in treating treatment-naïve myelofibrosis patients show that 91.7% of efficacy evaluable patients and78.6% of intent-to-treat (ITT) patients achieved a 35% or greater spleen volume reduction (SVR35) at week 24. Moreover, 77.8% of efficacy evaluable patients and 58.3% ITT patients achieved a 50% or greater reduction of their total symptom score (TSS50) at week 24. As a co-sponsor of the global registrational Phase III trial, Antengene will participate in the planning and conduction of the trial in the Mainland of China. Endometrial Cancer: Updated exploratory subgroup analyses from the Phase III "SIENDO" study of selinexor as a maintenance therapy in patients with advanced or recurrent endometrial cancer showed a median progression free survival (PFS) of 27.4 months among TP53 wild-type endometrial cancer patients who were treated with selinexor as a maintenance therapy, compared to 5.2 months in the placebo cohort. Karyopharm is currently conducting the "XPORT-EC-042" study, a registrational Phase III trial in the US for indication expansion into the maintenance setting for endometrial cancer. Topline data are expected in late 2024-2025. A U.S. approval could open the door to registration in Antengene's territories. 3. Fast-Growing Pan-APAC commercialization of XPOVIO® spotlighting the new partnership with Chinese pharmaceutical company Hansoh Pharma for the commercialization of XPOVIO® in the Mainland of China In the first six months of 2023, XPOVIO® obtained a New Drug Application (NDA) approval in Hong Kong China, achieved expansion in the insurance coverage by the Australian Pharmaceutical Benefits Scheme (PBS) to the XVd regimen, beyond the initially included Xd regimen, and was included into the Cancer Drug List in Singapore. Moreover, Antengene has completed an NDA submission for XPOVIO® in Indonesia. Antengene plans to submit a supplementary NDA (sNDA) for XPOVIO® for the treatment of relapsed/refractory diffuse large B-cell lymphoma in China in 2H 2023. The exclusive partnership with Hansoh Pharma for the commercialization of XPOVIO® in the Mainland of China positions Antengene to achieve greater national coverage across a larger number of cities, hospitals, prescribers, and maximizes the opportunity for future National Reimbursement Drug List (NRDL) inclusions. Deal terms include upfront payment of up to RMB200 million and future milestone payments of up to RMB535 million. Antengene will continue to record revenues from sales of XPOVIO® in the Mainland of China and Hansoh Pharma will charge a service fee to Antengene. 4. A Strong Cash and Bank Balance to Provide Runway Beyond 2025 As of June 30th, 2023, the company has a cash and bank balance of RMB1.32 billion. This strong cash and bank balance together with careful spending enables the continuous growth, development, and operation of Antengene beyond 2025. Antengene plans to release the updated data across its clinical portfolio at the annual R&D Day in November 2023. To learn more about the interim financial results of 2023, please see the full announcement at: https://www.antengene.com/static/upload/sofa/20230825/ca85e689b58595b3ca19ed5944a1ccfb.pdf About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000
HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Magnum Opus Acquisition Limited (NYSE: OPA) ("Magnum Opus" or the "Company") announces that on August 22, 2023, as a result of the Company's failure to timely file with the Securities and Exchange Commission ("SEC") its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the "June 2023 Form 10-Q"), it received a notice from the New York Stock Exchange (the "NYSE") stating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual (the "NYSE Rules"). Under the NYSE Rules, the Company has six months from the due date of the June 2023 Form 10-Q, or until February 21, 2024 (the "Deadline"), to file the June 2023 Form 10-Q. The Company can regain compliance with the NYSE Rules at any time prior to the Deadline by filing the June 2023 Form 10-Q. If the Company fails to file the June 2023 Form 10-Q before the Deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The NYSE notice has no immediate effect on the listing or trading of the Company's securities on the NYSE. As previously disclosed by the Company in a Notification of Late Filing on Form 12b-25 filed with the SEC on August 14, 2023, the Company was unable to file its June 2023 Form 10-Q by its original deadline without unreasonable effort or expense due to the fact that the Company required additional time to complete its financial statements and other disclosures in the June 2023 Form 10-Q. While the Company is working diligently to complete the June 2023 Form 10-Q and plans to file the June 2023 Form 10-Q as soon as practicable, the exact timing of the filing is uncertain at this moment. About Magnum Opus Magnum Opus Acquisition Limited is a special purpose acquisition company sponsored by L2 Capital, a private investment firm. Magnum Opus is a partnership of enterprise builders and public and private market investment specialists with extensive experience operating and investing throughout the business life cycle from founding, scaling operations through public listing. Magnum Opus aims to partner with public ready enterprises at the forefront of convergence of consumption and technology. Magnum Opus' mission is to support companies to realize their vision as they embark on their journey into the public markets and face new opportunities, challenges and stakeholders Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Certain of these forward-looking statements can be identified by the use of words such as "believes," "expects," "intends," "plans," "estimates," "assumes," "may," "should," "will," "seeks," or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company's ability to comply with SEC rules and the continued listing requirements of the NYSE. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements. Investor Relations Contact ICR, LLCRobin YangEmail: ICR-TMT@icrinc.com
BENGALURU, India and WARSAW, Poland, Aug. 25, 2023 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced a multi-year partnership with women's tennis World No.1 Iga Świątek. The 22-year-old is already a four-time Grand Slam Champion and one of the most dominant forces in the women's game today, who has been ranked World No. 1 since April 22, for a record 70 consecutive weeks. She has bettered her skills and capabilities in the face of every new challenge to rise to the top. Businesses and individuals seeking to navigate their next can draw inspiration from how she has steadily evolved to become a champion. Infosys Welcomes Tennis World No.1 Iga Świątek as Global Brand Ambassador to Promote Infosys’ Digital Innovation and Inspire Women Around the World Infosys has helped reimagine tennis for over eight years as the digital innovation partner for the ATP Tour, Roland-Garros, Australian Open, and The International Tennis Hall of Fame. The company has transformed the experience of the game for the tennis ecosystem leveraging advanced digital technologies like artificial intelligence (AI), cloud, and data analytics. Infosys will now work closely with Świątek's team to build an advanced data analytics and video dashboard by leveraging AI to amplify her training and help rapidly evolve her strengths and match strategy through continuous learning. Several of Infosys' clients embrace a similar approach, taking advantage of digital advances like AI, machine learning, cloud, and more to accelerate their evolution and transformation. Infosys and Świątek will also work together to create programs to inspire and empower young women around the world - for example, conceptualizing, and promoting programs to help women from underserved communities build careers in science, technology, engineering, and mathematics (STEM). Iga Świątek, said, "I am delighted to collaborate with an organization like Infosys that's bringing their knowledge of technology to change the tennis experience for so many people. Although tennis and technology may seem quite different at first, there's so much in common – including strategic thinking, learning and developing in every situation, the ability to evolve your game, and adjust. I am also moved by all that Infosys is doing off the court to bring more opportunities that empower people, businesses, and communities to move into the future. With Infosys, our goal is to also inspire people, especially young women, to prepare themselves to play strong and meaningful roles in a world that is not possible to live in and thrive without strong digital skills and knowledge." Tune in to Infosys brand ambassador Iga Świątek talk about her collaboration with Infosys: bit.ly/champions_evolve Salil Parekh, Chief Executive Officer & Managing Director, Infosys, said, "We are thrilled to welcome Infosys' new brand ambassador – Iga Świątek - a Polish hero who has hurdled immense challenges to become the top tennis player in the world, and an inspiration for everyone who aspires to navigate their next. Her relentless evolution mirrors the digital transformation journey that several of our clients undertake in collaboration with us to become champions in their own industries. Iga is also a great inspiration for women achievers and together with her, Infosys will work to inspire young people, especially women, to push forward and pursue STEM careers that are vital for our future. All of us at Infosys wish Iga the very best for the future." To know more about this partnership, please visit: www.infosys.com/championsevolve About Infosys Infosys is a global leader in next-generation digital services and consulting. Over 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in more than 56 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace. Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next. Safe Harbor Certain statements in this release concerning our future growth prospects, or our future financial or operating performance are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, our ability to attract and retain personnel, our transition to hybrid work model, economic uncertainties, technological innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, and our corporate actions including acquisitions. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2023. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.
Seizes market opportunities & scales up new businesses to empower second growth curve Results Highlights Product mix optimisation proved effective, with the mid-to-high-end and large-screen strategy driving a 12.4% year-on-year increase in gross profit to HK$6,500 million and a 1.4 percentage points year-on-year increase in overall gross profit margin to 18.6% As a result of increasing economies of scale, the Group's profit after tax increased by 7.8% year-on-year to HK$316 million and its profit attributable to owners of the parent increased by 5.7% year-on-year to HK$264 million TCL smart screens recorded a 12.9% year-on-year increase in shipments to 11.46 million sets. The global market share of TCL smart screens in terms of shipments and sales revenue increased by 1.3 percentage points and 1.5 percentage points to 12.4% and 10.2%, ranking among the top two and three in the world, respectively[1] Shipments of TCL smart screens of 65 inches and above increased by 67.8% year-on-year and accounted for 22.5% of TCL's total smart screen shipments, representing an increase of 7.4 percentage points year-on-year Global shipments of TCL Mini LED smart screens increased by 114.5% year-on-year, while global shipments of quantum dot ("QLED") smart screens increased by 69.9% year-on-year Innovative business recorded robust revenue growth of 65.2% year-on-year to HK$8,688 million HONG KONG, Aug. 25, 2023 /PRNewswire/ -- TCL Electronics Holdings Limited ("TCL Electronics" or the "Company", 01070.HK) today announced its interim results for the six months ended 30 June 2023 (the "Period"). Leveraging the mid-to-high-end strategy and the "TCL + Falcon" dual-brand strategy, its top-tier global brand influence, innovative technology capabilities, and the advantages of its vertically integrated industrial chain, TCL Electronics seized market opportunities during the Period, rapidly scaling up its business to achieve high-quality growth and steady operational improvements. During the Period, the Company's revenue amounted to HK$34,916 million, representing a year-on-year increase of 3.7%. Thanks to its effective product mix optimisation efforts through the mid-to-high-end and large-screen strategy, gross profit increased by 12.4% year-on-year to HK$6,500 million, while the overall gross profit margin improved by 1.4 percentage points year-on-year to 18.6%. In terms of expenses, the Company continued to reduce costs and enhance operational efficiency, with the administrative expense ratio dropping by 0.5 percentage points year-on-year. In the first half of 2023, TCL Electronics continued to promote the rapid development of innovative businesses such as distributed photovoltaics and Augmented Reality ("AR") and Extended Reality ("XR") smart glasses by leveraging the advantages that TCL has accumulated over the years in the display business, namely global brand power, a comprehensive distribution network, and vertical integration across the entire value chain. The Company also continued to utilise its internet business as a value-added service to empower its core business, and expand the all-category product offering of its "intelligent IoT (internet of things) ecosystem" with smart display products at its core. As a result of increasing economies of scale, during the Period, the Company's profit after tax increased by 7.8% year-on-year to HK$316 million and its profit attributable to owners of the parent amounted to HK$264 million, representing a year-on-year increase of 5.7%. Display Business Remained a Global Market Leader, Brand Advantage Drove Rapid Business Growth and Continued Margin Expansion With demand for large-screen TVs becoming the dominant trend in the industry, TCL Electronics is focusing on executing its "mid-to-high-end + large-screen" strategy and the "TCL + Falcon" dual brand strategy. By focusing on the mid-to-high-end market, the Company's display business has continued to lead in terms of scale and achieved significant breakthroughs in year-on-year growth. In the first half of 2023, TCL smart screens recorded a 12.9% year-on-year increase in shipments to 11.46 million sets. The global market share of TCL smart screens in terms of shipments and sales revenue increased by 1.3 percentage points and 1.5 percentage points to 12.4% and 10.2%, ranking among the top two and three in the world, respectively. Shipments of TCL smart screens of 65 inches and above increased by 67.8% year-on-year, and accounted for 22.5% of TCL's total smart screen shipments, representing an increase of 7.4 percentage points year-on-year. The average size of TCL smart screens increased by 3.6 inches year-on-year to 49.9 inches. In the PRC market, overall consumption in the TV industry remained weak, but TCL Electronics outperformed the industry average, driven by its enhanced brand power, optimised domestic distribution channels, and the 618 Shopping Festival in the first half of 2023. Shipments of TCL smart screens in the PRC market increased by 12.8% year-on-year in the first half of 2023, while shipments in the second quarter of 2023 increased by 14.0% year-on-year and 43.1% quarter-on-quarter. The corresponding revenue increased by 9.2% year-on-year to HK$6,898 million, or 16.8% year-on-year denominated in Renminbi and excluding exchange rate effects. The corresponding gross profit margin for the first half of 2023 remained flat year-on-year at 22.2%. Gross profit margin for the second quarter increased by 3.2 percentage points quarter-on-quarter, reflecting the significant boost in gross profit margin levels resulting from the launch of new TCL smart screen products in the second quarter. In international markets, despite global economic uncertainty, the Company successfully expanded its global market through a well-established global supply chain and sales network. In the first half of 2023, the shipment volume of TCL smart screens in international markets increased by 12.9% year-on-year, and at the same time, its shipment-based market share of TCL smart screens ranked among the top five nearly 30 countries[2]. During the Period, TCL Electronics recorded a 6.0% year-on-year increase in revenue from TCL smart screens in international markets to HK$14,144 million, with gross profit margin remaining stable, increasing by 0.8 percentage points year-on-year to 17.8%, demonstrating the strong resilience of the smart screens business. Internet Business and Innovative Business Sustained Strong Revenue Growth, Empowering the Company's Second Growth Curve The internet business and the innovative business performed well and maintained strong growth during the Period, empowering the Company's efforts to achieve profitable growth in sectors with blue ocean market opportunities. Internet Business In the first half of 2023, the Company's global internet business recorded revenue of HK$1,113 million, as continuous improvements in content quality led users to favour its smart screen products. In order to create an easy-to-use TV interface and further enhance user experience, TCL Electronics introduced its first fully customizable UI interface - LingKong UI (靈控UI), which won the 2023 German "Red Dot Design Award". LingKong UI has established in-depth partnerships with several leading video streaming platforms such as iQiyi, Tencent Video, and Youku to provide users with high-quality content. In addition, during the Period, the Company launched the internet TV industry's first custom content vertical generated by AI large language model technology - the "Super Story Painter" (超級智繪) AI story collection - aiming to efficiently generate intelligent device content and promote user interaction through innovative technology. In the international market, TCL Electronics maintained close cooperation with prominent internet giants such as Google, Roku, and Netflix to continually enhance user experience. The Company increased its monetisation capability by reaching out to the vast audience of TCL smart screen users through partnerships with OTT platforms. As of the end of June 2023, TCL Channel, the Company's integrated content application, is available in 60 countries in North America, Europe, Central and South America, and Asia Pacific, with a total user base of over 21 million. In the first half of 2023, the Company's revenue from the international internet business reached HK$226 million, representing a substantial increase of 77.1% year-on-year. Innovative Business In addition to the solid development of its core business, TCL Electronics seized the opportunity to continuously develop the innovative business through its well-established advantages. In the first half of 2023, the innovative business recorded robust revenue growth of 65.2% year-on-year to HK$8,688 million, making it a significant new growth engine of the Company. The Company's photovoltaic business, which officially commenced operations in the second quarter of 2022, exceeded HK$1,685 million in revenue, representing more than eightfold growth year-on-year. This remarkable performance was enabled by the business unit's complete upstream photovoltaic industry chain, extensive financial partnership resources, and plentiful industrial and commercial project opportunities both domestically and overseas. Building upon its established channel coverage and penetration in the PRC market, the Company's distributed photovoltaic business has achieved continued expansion in both the B2B (business-to-business) and B2C (business-to-customer) segments. As of the end of June 2023, the Company's photovoltaic business had extended its coverage to 14 major provinces and cities in the PRC, with an increase of more than 35 new industrial and commercial contracted projects, more than 350 new channel distributors, and reached a total of more than 10,000 contracted farmers. During the Period, leveraging its robust global brand power and comprehensive channel advantages, TCL Electronics promoted the continuous growth of its global all-category distribution businesses, which includes smart appliances such as air conditioners, refrigerators, and washing machines under the TCL brand. Revenue from the all-category marketing segment increased by 43.0% year-on-year to HK$6,073 million. According to the latest ChinaIOL report on shipments in the first half of 2023, TCL air conditioners ranked fourth globally. Various new products garnered prestigious industry accolades such as the "iF Design Award" and "Red Dot Design Award", further enhancing TCL's brand reputation. In addition, TCL Electronics maintained its leading position in the AR industry. In the second quarter of 2023, sales volume of RayNeo smart glasses ranked the first in AR consumer-grade market in the PRC[3]. During the 618 Shopping Festival, TCL NXTWEAR smart glasses achieved remarkable success on both JD.com and Tmall, securing top positions in both sales volume and sales revenue in the AR category[4]. Outlook: Core Display Business to Grow Market Share and Profitability, while Innovative Business Scales Up to Empower Second Growth Curve and Strengthen the Company's Global Leadership Position In terms of its core display business and technology, TCL Electronics will focus on mid-to-high-end products and continue to implement the "TCL + Falcon" dual-brand strategy, optimising its domestic and overseas channel layout while improving the product mix. This strategy aims to solidify the Company's position as a global leader and foster high-quality growth. Meanwhile, the Company will effectively leverage the brand power and channel resources it has accumulated in its core business over the years in its new business categories. It will boost investment in the internet business with a focus on enhancing the user experience. The Company will also increase investment in the photovoltaics and AR smart glasses businesses to capture blue ocean growth opportunities in these new business lines and create a seamless and comfortable "intelligent IoT ecosystem" to drive the Company's long-term growth. Meanwhile, the Company aims to capitalise on favourable factors such as the rebound in consumption and supportive national policies to expedite the growth of the smart device industry and expand into emerging sectors. Focusing on enhancements in the five key areas of products, operations, marketing, organisation and creativity, the Company will also leverage its competitive strengths and adhere to its "Value Led by Brand with Relative Cost Advantage, Ultimate Efficiency Management and Collaborative Innovation" strategy to empower the twin development goals of "Globalisation" and "Technological Transformation", and reinforce vertical integration throughout the entire industrial chain, advancing towards the goal of becoming a world-leading smart device enterprise. [1] Source: Global shipment and sales revenue data of the first half of 2023 from Omdia. [2] Sources: GfK, TV shipments data from January 2023 to June 2023; NPD, TV retail sales data from January 2023 to June 2023 [3] Source: CINNO Research [4] Statistical time interval of JD platform: 23 May 2023 to 18 June 2023; statistical time interval of Tmall platform: 31 May 2023 to 18 June 2023. About TCL Electronics TCL Electronics Holdings Limited (01070.HK, incorporated in the Cayman Islands with limited liability) was listed on the mainboard of the Hong Kong Stock Exchange in November 1999. It is engaged in display business, innovative business and internet business. TCL Electronics actively transforms and innovates under the strategy of "Value Led by Brand with Relative Cost Advantage, Ultimate Efficiency Operation and Collaborative Innovation". Focusing on the mid-to-high-end markets around the world, the Company strives to consolidate the "intelligent IoT ecosystem" strategy and is committed to providing users with an all-scenario smart and healthy life while developing into a world-leading smart technology company. TCL Electronics is part of the Shenzhen-Hong Kong Stock Connect program and is included in the Hang Seng Stock Connect Hong Kong Index, the Hang Seng Composite MidCap & SmallCap Index and the Hang Seng Corporate Sustainability Benchmark Index. Besides, it has received Hang Seng Index's ESG rating of A for five consecutive years since 2018. For more information, please visit the investor relations web page of TCL Electronics at http://electronics.tcl.com or follow the WeChat Official Page of TCL Electronics investor relations.
A12 藝術空間
partnership
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
